TNF and leishmaniasis: Twenty-five (51%) patients were under infliximab treatment at the moment of leishmaniasis diagnosis, twenty (40.8%) were receiving adalimumab, two (4.1%) were receiving etanercept, one (2%) golimumab and another one (2%) received a non-specified TNF-α blocker.